Gregory Botta

💡 With a $1 million grant from @TheVFoundation, Moores Cancer Center and @salkinstitute are changing the course of pancreatic cancer treatment. Dr. Gregory Botta is collaborating with Salk's Diana Hargreaves to improve immunotherapy treatments, identify potential biomarkers and elevate patient outcomes. 🔗 Read more: bit.ly/4kS4d5d

@Aiims1742 @skopetz @DrShubhamPant @DavidHongMD Every vehicle on the island!

Revolution Medicines new pipeline just dropped.

Our expert team's new publication on the Association of personalized and tumor-informed #ctDNA with patient survival outcomes in #pancreaticcancer academic.oup.com/oncolo/article… @UCSDCancer

New #JITC case report: Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cells bit.ly/4bvXmuG @gregorybotta @Kaufm020 @DrEzraCohen

Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cells | Journal for ImmunoTherapy of Cancer jitc.bmj.com/content/12/2/e…

It’s official! It is my absolute privilege to be named as the Director of the Moores Comprehensive Cancer Center at UCSD Health. I am looking forward to advancing efforts in cancer based on an approach of collaboration and excellence.

UCSD Faculty member, Dr. Andy Lowy delivering the MSKCC David Rubenstein Award Lecture in New York City. Prestigious award given annually for impacting the understanding, diagnosis and/t management of pancreatic cancer eradication Congratulations Dr. Lowy!

Day 1 at #ESMOWest2023 was a blast! 🚀 A special thank you to our fantastic speakers today for sharing their incredible expertise! @marklewismd @gregorybotta @Dr_RaviMadan @marcellorotta1 @MikeLattanzi @drkomanduri @bvantine1 #MedEd #Oncology #MedTwitter

Honored to chair this outstanding conference. 💥🔥🌈🎯 Nigel and Deanna Russell at Genome Web did a great job. The speakers were so incredible that people were not looking at their iPhones. Bring together academia, industry, patients to transform precision oncology

@PatelOncology ctDNA has the potential to differentiate radiologic progression vs flare: nature.com/articles/s4301…

With neoadjuvant IO there is potential for nodal flare where lymph nodes look worse on CT, but at resection the patients have no cancer in those LN. Would only abort surgery for clinical PD or biopsy confirmed distal PD, not for LN #tinacascone nature.com/articles/s4146…

Plus chat with GI medical oncologist @gregorybotta from @UCSDCancer and pancreatic cancer survivor Russ Gold @Justice_in_SD @PanCANSanDiego Register now! See you there!

🆕Just published🗞️ One of the 1st insights on🩸#ctDNA in patients with #AnalCancer. Of value in a number of ways & clinical settings with how the field is evolving including use of #immunotherapy➕deeper insights from sequencing🧬. @OncoAlert @OncJournal academic.oup.com/oncolo/advance…

Happy to share our publication on tumor-informed circulating tumor DNA in patients with gastric, GEJ, and esophageal cancers. See our @JCOPO_ASCO manuscript out today: ascopubs.org/doi/full/10.12… #ctDNA

👇🏾🆕 @JCOPO_ASCO Delighted to be a part of this important project - one of the largest datasets providing in-depth insights & analyses into #ctDNA🩸🧬 in stomach & esophageal cancers. #STCSM #ESOCSM ➡️Sets the foundation for #MRD-driven📚. @OncoAlert 📌ascopubs.org/doi/full/10.12…

GI Cancers Series Part 3: Immunotherapy and Targeted Therapy in GI Cancers CURE® 12/6/22, 6:00 PM GMT -4 summer John L. Marshall @gregorybotta @GIcancerDoc @MarthaRaymond10 docmeetings.com/events/1908fa1…

ASCO 2022 on the Multicenter Phase Ib US Trial of Salvage CT041 CLDN18.2-Specific CAR T-Cell Therapy for Advanced Gastric and Pancreatic Adenocarcinoma | VuMedi vumedi.com/video/asco-202… via @vumedi

We are honored to announce that Erkki Ruoslahti has been named a #LaskerLaureate. The #LaskerAward is the most prestigious American award for biomedical research, and has been called the "American Nobel" @LaskerFDN #Lasker2022 #LaskerAward bit.ly/ruoslahtilaske…